DeepMed Research

ALKERMES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.alkermes.com

Clinical Trials

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

Completed

Conditions: Schizophrenia

First Posted Date: 2019-04-18

Last Posted Date: 2023-02-02

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 338

Registration Number: NCT03919994

Locations: 🇺🇸
Alkermes Investigational Site, Salt Lake City, Utah, United States

Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo oral capsule
Drug: RDN-929 TBD dose
Drug: RDN-929

First Posted Date: 2018-09-12

Last Posted Date: 2020-02-20

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 84

Registration Number: NCT03668314

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

Phase 3

Terminated

Conditions: Refractory Major Depressive Disorder

Interventions: Drug: ALKS 5461

First Posted Date: 2018-08-01

Last Posted Date: 2021-07-16

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 175

Registration Number: NCT03610048

Locations: 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico

A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density

Early Phase 1

Completed

Conditions: Healthy
Alzheimer Disease

Interventions: Other: [11C]-UCB-J

First Posted Date: 2018-07-05

Last Posted Date: 2020-02-20

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 19

Registration Number: NCT03577262

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
🇳🇱
University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands
🇳🇱
VU Medical Center, Dept. Radiology and Nuclear Medicine, Amsterdam, Netherlands

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Combination Product: Aripiprazole Lauroxil
Drug: Paliperidone Palmitate

First Posted Date: 2017-11-17

Last Posted Date: 2020-08-11

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 200

Registration Number: NCT03345979

Locations: 🇺🇸
Alkermes Investigational Site, Richardson, Texas, United States

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Phase 3

Completed

Conditions: Bipolar I Disorder
Schizophrenia
Schizophreniform Disorder

Interventions: Drug: ALKS 3831

First Posted Date: 2017-06-28

Last Posted Date: 2024-02-12

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 524

Registration Number: NCT03201757

Locations: 🇬🇧
Alkermes Investigational Site, Headington, United Kingdom

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder
Schizophreniform Disorders
Schizophrenia

Interventions: Drug: ALKS 3831
Drug: Olanzapine

First Posted Date: 2017-06-15

Last Posted Date: 2023-01-19

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 426

Registration Number: NCT03187769

Locations: 🇬🇧
Alkermes Investigational Site, Maidstone, United Kingdom

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: ALKS 5461 Placebo
Drug: ALKS 5461

First Posted Date: 2017-06-15

Last Posted Date: 2021-04-08

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 278

Registration Number: NCT03188185

Locations: 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
🇺🇸
Alkermes Investigative Site, Bellevue, Washington, United States

An Insulin Sensitivity Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: ALKS 3831
Drug: Olanzapine

First Posted Date: 2016-10-04

Last Posted Date: 2017-08-22

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 60

Registration Number: NCT02922426

Locations: 🇺🇸
Alkermes Investigational Site, Chula Vista, California, United States

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: ALKS 3831

First Posted Date: 2016-08-19

Last Posted Date: 2021-07-21

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 266

Registration Number: NCT02873208

Locations: 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy